Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

PIK3CA Biological Pathways Reviews

Videos

Alberto Montero, MD, UH Seidman Cancer Center
Videos
STX-478 Demonstrates Promise in Heavily Pre-Treated Patients With PI3Kα-Mutated Solid Tumors
10/17/2024
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
Inavolisib vs Alpelisib Plus Fulvestrant For Patients With PIK3CA-Mutated Advanced Breast Cancer
09/24/2024
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
First-Line Capivasertib Plus Paclitaxel Fails to Improve OS in Metastatic Triple-Negative Breast Cancer
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
Inavolisib Plus Palbociclib and Fulvestrant for Patients With Relapsed PIK3CA-Mutated Advanced Breast Cancer
09/03/2024
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Expert Roundtable
Videos
Selecting Optimal First-Line Therapies for Patients With Acute Myeloid Leukemia
11/07/2024
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert...
11/07/2024
Oncology
Expert Roundtable
Videos
Diagnosis and Risk Stratification of Acute Myeloid Leukemia
11/07/2024
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert...
11/07/2024
Oncology
Videos
Best Management Practices for a Patient With Early-Stage Non-Small Cell Lung Cancer
11/05/2024
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of...
11/05/2024
Oncology
John Leonard, MD
Videos
Highlights in Novel Therapies for Lymphomas From the LL&M Congress
11/05/2024
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Hodgkin Lymphoma From the LL&M Congress
11/05/2024
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Diffuse Large B-Cell Lymphoma From the LL&M Congress
11/05/2024
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Mantle Cell Lymphoma From the LL&M Congress
11/05/2024
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
Jonathan Riess, MD
Conference Coverage
IO102-IO103 Plus Pembrolizumab Demonstrates Potential for Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
10/31/2024
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses...
10/31/2024
Oncology
Elisabeth Livingstone, MD
Conference Coverage
Early Switch From Targeted to Immunotherapy for Patients With Advanced BRAF V600-Positive Melanoma
10/31/2024
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD,...
10/31/2024
Oncology
Andrea Botticelli, MD
Conference Coverage
Using Comprehensive Genome Profiling to Guide Treatment for Patients With Metastatic Solid Tumors
10/31/2024
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD,...
10/31/2024
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

News
Tumor Molecular Features Contribute Substantially to Overall Survival Disparities Among Patients With Colorectal Cancer
11/05/2024
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
10/10/2024
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer
10/02/2024
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
Evaluating Inavolisib vs Alpelisib Plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
09/24/2024
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
Inavolisib, Palbociclib And Fulvestrant As Potential New Standard of Care for Patients With PIK3CA-Mutated, HR-Positive, HER2-Negative Breast Cancer
12/08/2023
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Quizzes

Quiz
Progression-Free Survival in the INAVO120 Trial
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
Incidence of PIK3CA Mutations in Breast Cancer
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Quiz
Adjuvant Pembrolizumab Plus Chemotherapy for Patients With Newly Diagnosed, High-Risk Endometrial Cancer
11/12/2024
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase...
11/12/2024
Oncology
Quiz
Using the PREMM5 Model to Detect Mutations Associated With Lynch Syndrome
11/06/2024
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene...
11/06/2024
Oncology
Quiz
Use of Luspatercept for Patients With Myelofibrosis-Associated Anemia
10/16/2024
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to...
10/16/2024
Oncology
Quiz
Comparing Custom Targeted DNA Sequencing Panel vs FISH for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
Low-Dose Subcutaneous Decitabine Treatment for Patients With MF
10/11/2024
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to...
10/11/2024
Oncology
Quiz
Ibrutinib Plus Venetoclax for Patients With TP53-Mutated MCL
10/11/2024
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented...
10/11/2024
Oncology
Quiz
Long-Term Results of Acalabrutinib-Based Regimens in CLL
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Quiz
Use of Pirtobrutinib Among Patients With B-Cell Malignancies With Richter Transformation
10/08/2024
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an...
10/08/2024
Oncology
Quiz
SHR-A1811 for HER2-Expressing Advanced Solid Tumors
10/03/2024
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811...
10/03/2024
Oncology
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Tumor Molecular Features Contribute Substantially to Overall Survival Disparities Among Patients With Colorectal Cancer
11/05/2024
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
10/10/2024
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer
10/02/2024
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
Evaluating Inavolisib vs Alpelisib Plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
09/24/2024
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
Inavolisib, Palbociclib And Fulvestrant As Potential New Standard of Care for Patients With PIK3CA-Mutated, HR-Positive, HER2-Negative Breast Cancer
12/08/2023
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement